Home Publications

Publications and presentations related to our technology and programs are listed below.

Fc Optimization Platform

Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization
Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Johnson S, Koenig S, Bonvini E. Advances in Enzyme Regulation 2007 December 3.

DART® Platform

Keystone 2018 - Tailoring Cytolytic Activity, Proliferation and Cytokine Release via CD3 Engineering of DART® Molecules for Redirected T-cell Killing
Huang L, La-Motte Mohs R, Kao Lam C-Y, Liu L, Kaufman T, Chichili G, Alderson R, Stahl K, Brown JG, Moore P, Johnson S and Bonvini E

Application of dual-affinity re-targeting (DART) molecules to achieve optimal redirected t-cell killing of b-cell lymphoma
Paul A. Moore, Wenjun Zhang, G. Jonah Rainey, Steve Burke, Hua Li, Ling Huang, Sergey Gorlatov, Maria Concetta Veri, Sudeppta Aggarwal, Yinhua Yang, Kaplana Shah, Linda Jin, Sunan Zhang, Leilei He, Tengfei Zhang, Valentina Ciccarone, Scott Koenig, Ezio Bonvini and Syd Johnson; Blood, 2011; 117(17):4542-4551.

Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer
Root AR, Cao W, Li B, LaPan P, Meade C, Sanford J, Jin M, O’Sullivan C, Cummins E, Lambert M, Sheehan AD, Ma W, Gatto S, Kerns K, Lam K, D’Antona AM, Zhu L, Brady WA, Benard S, King A, He T, Racie L, Arai M, Barrett D, Stochaj W, LaVallie ER, Apgar JR, Svenson K, Mosyak L, Yang Y, Chichili GR, Liu L, Li H, Burke S, Johnson S, Alderson R, Finlay WJJ, Lin L, Olland S, Somers W, Bonvini E, Gerber H-P, May C, Moore PA, Tchistiakova L and Bloom L Antibodies 2016; 5(1): 6

Effector cell recruitment with novel fv-based dual-affinity retargeting protein leads to potent tumor cytolysis and in vivo b-cell depletion
Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, et al. J Mol Biol, 2010 Apr 9;399(3):436-49.

TRIDENT™ Platform

AACR 2019 - Tumor-antigen 5T4-dependent Activation of the CD137 Costimulatory Pathway by Bispecific 5T4 x CD137 TRIDENT™ Molecules
Liqin Liu, Ling Huang, Vatana Long, Yinhua Yang, Robert Burns, Jonathan Li, Jennifer DiChiara, Qihong Xu, Chia-Ying K. Lam, Jim Tamura, Valentina Ciccarone, Syd Johnson, Ezio Bonvini and Paul A. Moore

AACR 2019 - Selection of a Bispecific Trivalent HER2 x CD137 TRIDENT™ Format Providing Optimal Tumor-anchored Immune Co-stimulation
Liqin Liu, Chia-Ying K. Lam, Ralph Alderson, Vatana Long, Yinhua Yang, Robert Burns, Lusiana Widjaja, Jonathan Li, Christina Wolff, Valentina Ciccarone, James Tamura, Gundo Diedrich, Ezio Bonvini, Syd Johnson, Paul A. Moore

Margetuximab (anti-HER2)

SABCS 2019 - Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis
Hope S. Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Mark D. Pegram, Antonino Musolino, Thomas Bachelot, Gail S. Wright, Michelino De Laurentiis, Peter A. Kaufman, Timothy Pluard, Francesco Ricci, Lupe G. Salazar, Denise A. Yardley, Sutton Edlich, Shengyan Hong, Edwin Rock, William J. Gradishar, on behalf of the SOPHIA Study Group

SABCS 2019 - Phase 3 SOPHIA Study of Margetuximab + Chemotherapy vs Trastuzumab + Chemotherapy in Patients With HER2+ Metastatic Breast Cancer After Prior Anti-HER2 Therapies: Infusion Time Substudy Results
William J. Gradishar, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Mark D. Pegram, Antonino Musolino, Rossana Berardi, Michelino De Laurentiis, Shakeela W. Bahadur, Young-Hyuck Im, Cynthia Lynch, Yelena Novik, Sutton Edlich, Edwin Rock, Shengyan Hong, and Hope S. Rugo, on behalf of the SOPHIA Study Group

ESMO 2019 - Margetuximab plus Pembrolizumab for Treatment of Patients with HER2-Positive Gastroesophageal Adenocarcinoma (GEA) Post-Trastuzumab: Survival Analysis
D.V.T. Catenacci, H. Park, H.E. Uronis, Y.-K. Kang, M. Ng, P.C. Enzinger, K.-W. Lee, K.H. Lim, P.J. Gold, J. Lacy, S.H. Park, K. Huber, A. Wynter-Horton, J. Nordstrom, Y. Yang, P. Moore, D. Li, T. Wu, J. Wigginton, J. Baughman, M. Rosales, J. Davidson-Moncada, Y. J. Bang

ESMO 2019 - Determinants of Response of HER2+ Gastric Cancer vs Gastroesophageal Junction Adenocarcinoma to Margetuximab plus Pembrolizumab post Trastuzumab
H. Park, H.E. Uronis, Y-K. Kang, M. Ng, P.C. Enzinger, K.W. Lee, S. Rutella, S. Church, J. Nordstrom, Y. Yang, P. Moore, D. Li, K. Knutson, C. Erskine, T. Wu, J. Yen, A. Franovic, J. Muth, M. Rosales, J. Vadakekolathu, J. Davidson-Moncada, Y.J. Bang, D.V.T. Catenacci

ESMO 2019 - Evaluation of Tumor Microenvironment Identifies Immune Correlates of Response to Combination Immunotherapy with Margetuximab (M) and Pembrolizumab (P) in HER2+ Gastroesophageal Adenocarcinoma (GEA)
S. Rutella, S.E. Church, J. Vadakekolathu, S. Reeder, A. Sullivan, S. Warren, J. Baughman, J. Muth, H. Park, H. Uronis, Y-K. Kang, M. Ng, P. Enzinger, K.W. Lee, K. Huber, A. Wynter-Horton, D. Li, Y-J. Bang, J. Davidson-Moncada, D. Catenacci

ASCO 2019 - SOPHIA Primary PFS Analysis: A Phase 3 Study of Margetuximab + Chemotherapy vs Trastuzumab + Chemotherapy in Patients With HER2+ Metastatic Breast Cancer After Prior Anti-HER2 Therapies
Hope S. Rugo, Seock-Ah Im, Gail S. Wright, Santiago Escrivá-de-Romaní, Michelino De Laurentiis, Javier Cortes, Shakeela W. Bahadur, Barbara B. Haley, Raul H. Oyola, David A. Riseberg, Antonino Musolino, Fatima Cardoso, Giuseppe Curigliano, Peter A. Kaufman, Mark D. Pegram, Sutton Edlich, Shengyan Hong, Edwin Rock, William J. Gradishar, on behalf of the SOPHIA Study Group

ASCO 2019 - High Frequency of HER2-specific Immunity Observed in Patients (pts) with HER2+ Cancers Treated with Margetuximab (M), An Fc-enhanced Anti-HER2 Monoclonal Antibody (mAb)
Jeffrey L. Nordstrom, John Muth, Courtney L. Erskine, Catherine Sanders, Erik C. Yusko, Ryan Emerson, Min-Jung Lee, Sunmin Lee,  Jane Trepel, Yung-Jue Bang, Seock-Ah Im,  Giuseppe Giaccone, Todd Michael Bauer, Howard A. Burris III, Jan E. Baughman, Edwin P. Rock, Paul A. Moore, Ezio Bonvini, KL Knutson

AACR 2019 - Margetuximab Mediates Greater Fc-dependent Anti-tumor Activities than Trastuzumab or Pertuzumab In Vitro
Liqin Liu, Yinhua Yang, Robert Burns, Jonathan Li, Haiquan Li, Sergey Gorlatov, Paul Moore, Jeffrey Nordstrom

ASCO GI 2019 - Antitumor Activity of Margetuximab plus Pembrolizumab in Patients with Advanced HER2+ (IHC3+) Gastric Carcinoma
Daniel V.T. Catenacci, Haeseong Park, Hope Elizabeth Uronis, Yoon-Koo Kang, Matthew C.H. Ng, Philip Jordan Gold, Peter C. Enzinger, Keun Wook Lee, Jill Lacy, Se Hoon Park, Jennifer Yen, Justin Odegaard,  Aleksandra Franovic, Sarah Church, Anushka DeCosta, Jan E. Baughman, Aisha Wynter-Horton, Francine Chen, Jeff Nordstrom , Paul A. Moore, Tony Wu, Jan Kenneth Davidson-Moncada, Yung-Jue Bang

SABCS 2018 - Long-Term Responders to Single-Agent Margetuximab, an Fc-Modified Anti-HER2 Monoclonal Antibody, in Metastatic HER2+ Breast Cancer Patients with Prior Anti-HER2 Therapy
S. A. Im, Y. J. Bang, D. Y. Oh, G. Giaccone, T. M. Bauer, J. L. Nordstrom, H. Li, P. A. Moore, S. Hong, J. E. Baughman, E. Rock, H. A. Burris

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Bang YJ, Giaccone G, Im SA, Oh DY, Bauer TM, Nordstrom JL, Li H, Chichili GR, Moore PA, Hong S, Stewart SJ, Baughman JE, Lechleider RJ, Burris HA. Ann Oncol. 2017 Apr 1;28(4):855-861

Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fc-gamma receptor binding properties
Nordstrom J, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S. Li H, Ciccarone V, Zhang T, Stavenhagen J, Koenig S, Stewart S, Moore P, Johnson S, Bonvini E. Breast Cancer Research, 2011 November 30;13:R123.

Flotetuzumab (CD123 x CD3)

ASH 2019 - Flotetuzumab, an Investigational CD123 x CD3 Bispecific DART® Protein, in Salvage Therapy for Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia Patients
Geoffrey L. Uy, Ibrahim Aldoss, Matthew C Foster, David A Sallman, Kendra L. Sweet, David A. Rizzieri, Peter H. Sayre, Anjali S. Advani, Ashkan Emadi, Matthew J. Wieduwilt, Norbert Vey, Fabio Ciceri, Matteo Giovanni Carrabba, Tamara Moyo, Sarah E. Church, Michael P. Rettig, Martha L. Arellano, John E. Godwin, Bob Löwenberg, GerwinHuls, FarhadRavandi, John Muth, Kathy Tran, Ouiam Bakkacha, Kenneth Jacobs, MojcaJongen-Lavrencic, Erin Timmeny, Max S. Topp, Stefania Paolini, KuoGuo, Teia Curtis, Jian Zhao, Jayakumar Vadakekolathu, Jon M. Wigginton, Ezio Bonvini, Sergio Rutella, M Roland B. Walter, Jan K Davidson-Moncada, and John F. DiPersi

ASH 2019 - Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123 ×CD3 Bispecific DART® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Sergio Rutella, Jayakumar Vadakekolathu, Mark D. Minden, Tressa Hood, Sarah E. Church, Stephen Reeder, Heidi Altmann, Amy H. Sullivan, Elena J. Viboch, Tasleema Patel, Narmin Ibrahimova, Sarah E. Warren, Andrea Arruda, Yan Liang, Marc Schmitz, Alessandra Cesano, Peter J.M. Valk, Bob Löwenberg, A. Graham Pockley, Martin Bornhäuser, Sarah K. Tasian, Michael P. Rettig, Jan Davidson-Moncada, John F. DiPersio

ASH 2019 - Flotetuzumab: an Investigational CD123xCD3 Bispecific DART® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies is Associated with Response to Treatment in Primary Refractory AML Patients
John E. Godwin, Carmen Ballesteros-Merino, Nikhil Lonberg, Shawn M. Jensen, Tarsem Moudgil, Carlo B. Bifulco, Sarah E. Church, Thomas Smith, Michael Bailey, James Gowen-MacDonald, Sergio Rutella, Jon M. Wigginton, John Muth, Jan Davidson-Moncada, Bernard A. Fox

ASH 2019 - A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Andrew H. Wei, Chun Yew Fong, Pau Montesinos, Maria Calbacho, Jordi Sierra, Jaime Perez De Oteyza, Jacob M. Rowe, Ofir Wolach, Yishai Ofran, Yakir Moshe, Jichao Sun, Jan Baughman, Eileen McNulty, Ezio Bonvini, Jon M. Wigginton and Jan K Davidson-Moncada

ASH 2018 - Phase 1 Cohort Expansion of Flotetuzumab, a CD123 x CD3 Bispecific DART® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Geoffrey L. Uy, MD, Michael P Rettig, PhD, Norbert Vey, MD, John Godwin, MD, Matthew Foster, MD, David A. Rizzieri, MD, Martha L. Arellano, MD, Max S. Topp, MD, Gerwin Huls, MD, PhD, Mojca Jongen-Lavrencic, MD, PhD, Giovanni Martinelli, MD, Stefania Paolini, MD, PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Kendra Sweet, MD, Farhad Ravandi, MBBS, Sarah E Church, PhD, Jayakumar Vadakekolathu, PhD, Sergio Rutella, MD, PhD, FRCPath, Jichao Sun, PhD, Kang Yang, Jan Baughman, MPH, Teia Curtis, PhD, Erin Timmeny, Kerri Cali, Kathy Tran, John Muth, MS, Ross La MotteMohs, PhD, Camille Poirot, Pharm.D., Athanasios Pallis, MD, Alessandra Cesano, MD, PhD, Ezio Bonvini, MD, Jon Wigginton, MD, Bob Löwenberg, MD, PhD, Jan K DavidsonMoncada, MD, PhD and John F DiPersio, MD, PhD

ASH 2018 - Biomarkers and Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific DART® Molecule for T-cell Redirected Therapy
Kenneth Jacobs, Cedric Viero, John Godwin, Jan Baughman, Jichao Sun, Kang Ying, John Muth, Shengyan Hong, Norbert Vey, Kendra L. Sweet, Geoffrey L. Uy, Farhad Ravandi, Matthew C Foster, David A. Rizzieri,  Martha L. Arellano, Michael P. Rettig, Max S. Topp, Gerwin Huls, Helene Lelièvre, Stefania Paolini, Fabio Ciceri, Matteo Giovanni Carrabba, Bob Löwenberg, John F. DiPersio, Jon Wigginton1 and Jan K. Davidson-Moncada

ASH 2018 - Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 ×CD3 Bispecific DART® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Sergio Rutella, Sarah E. Church, Jayakumar Vadakekolathu, Elena Viboch, Amy H. Sullivan, Tressa Hood, Sarah E. Warren, Alessandra Cesano, Ross La Motte-Mohs, John Muth, Helene Lelièvre, Bob Löwenberg, John F. DiPersio and Jan K. Davidson-Moncada

ASH 2018 - Bone Marrow T Cell Changes by Multiplex IHC After Treatment with Flotetuzumab, a CD123 x CD3 Bispecific DART® Protein, in a Primary Refractory t-AML Patient
John E. Godwin, Carmen Ballesteros-Merino, Carlo B. Bifulco, Helene Lelièvre, Jon M. Wigginton, Jan Davidson-Moncada, Bernard A. Fox

Keystone 2018 - Tailoring Cytolytic Activity, Proliferation and Cytokine Release via CD3 Engineering of DART® Molecules for Redirected T-cell Killing
Ling Huang, Ross La-Motte Mohs, Chia-Ying Kao Lam, Liqin Liu, Thomas Kaufman, Gurunadh Chichili, Ralph Alderson, Kurt Stahl, Jennifer G. Brown, Paul Moore, Syd Johnson and Ezio Bonvini

ASH 2017 - Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies
Michael P Rettig, John Godwin, Norbert Vey, Bernard Fox, Carmen Ballesteros-Merino, Carlo B Bifulco, Daner Li, Daniel Primo, Joan Ballesteros, Jichao Sun, Helene Lelièvre, Jan Baughman, Ross La Motte-Mohs, John Muth, Paul Moore, Ezio Bonvini,  Jon Wigginton, John F DiPersio and Jan Davidson-Moncada

Targeting CD123 in acute myeloid leukemia using a T-cell–directed dual-affinity retargeting platform
Al-Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, Gao F, Eades WC, Bonvini E, Chichili GR, Moore PA, Johnson S, Collins L and DiPersio JF Blood 2016 127:122-131  

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
Chichili G, Huang L, Li H, Burke S, He L, Tang Q, Jin L, Gorlatov S, Ciccarone V, Chen F, Koenig S, Shannon M, Alderson R, Moore P, Johnson S, Bonvini E. Sci Transl Med 27 May 2015; Vol. 7, Issue 289, 289ra82.

Enoblituzumab (anti-B7-H3)

SITC 2018 - A Phase 1, Open-Label, Dose Escalation Study of Enoblituzumab in Combination with Pembrolizumab in Patients with Select Solid Tumors
Charu Aggarwal, Anthony Joshua, Robert Ferris, Scott Antonia, Osama Rahma, Anthony Tolcher, Roger B. Cohen, Yanyan Lou, Ralph Hauke, Nicholas Vogelzang, Dan Zandberg, Arash Kalebasty, Victoria Atkinson,  Alex Adjei, Mahesh Seetharam, Ariel Birnbaum, Andrew Weickhardt, Vinod Ganju, Riva Bondarenko, Linda Peng, Tony Wu, Scott Currence, Jan Baughman, Ezio Bonvini, Stacie Goldberg, Jon Wigginton, Nehal Lakhani

SITC 2018 - Phase II Neoadjuvant and Immunologic Study of B7-H3 Targeting with Enoblituzumab in Localized Intermediate- and High-Risk Prostate Cancer
Eugene Shenderov, Karim Boudadi, Angelo DeMarzo, Mohamad E Allaf, Onur Ertunc, Igor Vidal, Carolyn Chapman, Hao Wang, Jim Vasselli, Jon Wigginton, Jan Davidson, Rehab Abdallah, Tanya O’Neal, Christian Pavlovich, Trinity Bivalacqua, Ashley E. Ross, Charles G. Drake, Drew Pardoll1 & Emmanuel S. Antonarakis

Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity
Loo D, Alderson R, Chen F, Huang L, Zhang W, Gorlatov S, Burke S, Ciccarone V, Li H, Yang Y, Son T, Chen Y, Easton A, Li J, Rillema J, Licea M, Fieger C, Liang T, Mather J, Koenig S, Stewart S, Johnson S, Bonvini E, Moore P. Clinical Cancer Research 2012; doi:10.1158/1078-0432.CCR-12-0715

MGC018 (B7-H3 ADC)

AACR 2017 - Preclinical Development of a Duocarmycin-based Antibody-Drug Conjugate Targeting B7-H3 for Solid Cancer
Thomas Son, Juniper A. Scribner, Jeff Hooley, Michael Chiechi, Pam Li, Tim E. Hotaling, Anushka De Costa, Yan Chen, Francine Chen, Bhaswati Barat, Ling Huang, Valentina Ciccarone, Timur Gaynutdinov, James Tamura, Scott Koenig, Syd Johnson, Paul A. Moore, Ezio Bonvini, Deryk Loo

SITC - A Phase 1/2, First-in-Human, Dose Escalation Study of MGC018 (Anti-B7-H3 Antibody-Drug Conjugate) Alone and in Combination with MGA012 (Anti-PD-1 Antibody) in Patients with Advanced Solid Tumors
John Powderly, Deryk Loo, Anthony Joshua, Johanna Bendell, Alexander Spira, Joanna Lohr, Pepi Pencheva, Jichao Sun, Jan Baughman, Ezio Bonvini, Jennifer Brown, Nehal Lakhani, Jon M Wigginton

MGA012 (anti-PD-1)

SITC 2019 - A Phase 1 Study of INCMGA00012, a PD-1 Inhibitor, in Patients With Advanced Solid Tumors: Preliminary Results for Patients With Advanced Cervical Cancer (POD1UM-101)
Janice M. Mehnert, Luis Paz-Ares, Joanna Pikiel, Udai Banerji, Anna Kryzhanivska, Nehal Lakhani, Sebastian Ochsenreiter, Tobias Arkenau, Deanna Kornacki, Chuan Tian, Thomas Condamine, Nawel Bourayou, Itziar Gardeazabal González

SITC 2019 - Preliminary Results of a Phase 2 Study of INCMGA00012 in Patients With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy
Sheela Rao, Jaume Capdevila, Duncan Gilbert, Stefano Kim, Laetitia Dahan, Talal Kayyal, Marwan Fakih, Anne Demols, Mark Cornfeld, Chuan Tian, Melissa Catlett, Jean-Philippe Spano

AACR 2019 - Pharmacodynamic Correlates in a Phase 1 Study of INCMGA00012, a PD-1 Antagonistic Monoclonal Antibody
Thomas Condamine, Sherry Owens, Pat Feldman, Ross La Motte-Mohs, John Muth, Bradley Sumrow, Paul Moore, Robert Newton

AACR 2019 - Assessment of Flat Dosing Strategy for INCMGA00012 in Patients With Advanced Tumors
Xuejun Chen, Phil Wang, Sanjeev Kaul, Bradley Sumrow, Swamy Yeleswaram

SITC 2018 - First-in-Human Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors: Interim Results of the Cohort Expansion Phase
Janice Mehnert, Anthony Joshua, Nehal Lakhani, Udai Banerji, Drew Rasco, Iwona Lugowska, Monica Tomaszewska-Kiecana, Elena Garralda, Deanna Kornacki, Bradley Sumrow, Nawel Bourayou, Chuan Tian, John Powderly

SITC 2017 - A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics (PK) of MGA012 (anti-PD-1 antibody) in Patients with Advanced Solid Tumors
Nehal Lakhani, Janice M. Mehnert, Drew Rasco, Michael Gordon, Joanna Lohr, Sharad Sharma, Hua Li, Ross LaMotte-Mohs, Paul Moore, Jichao Sun, Pepi Pencheva, Brad Sumrow, Jon Wigginton, John Powderly

SITC 2017 - Preclinical Characterization of MGA012, A Novel Clinical-stage PD-1 Monoclonal Antibody
Ross La Motte-Mohs, Kalpana Shah, Jennifer G. Brown, Ralph F. Alderson, Doug Smith, Sergey Gorlatov, Valentina Ciccarone, James K. Tamura, Hua Li, Jill R. Rillema, Monica Licea, Leilei He, Farha Vasanwala, Jessica Hill, Christina Wolff, Massimiliano Pascuccio, Francine Z. Chen, Yan Chen, Anushka De Costa, Ann Easton, Alexey Berezhnoy, Jonathan Li, Jeffrey Nordstrom, Scott Koenig, Ezio Bonvini, Syd Johnson and Paul A. Moore

MGD013 (PD-1 x LAG-3)

SITC 2017 - Preclinical Characterization of MGD013, a PD-1 x LAG-3 Bispecific DART® Molecule
Ross La Motte-Mohs, Kalpana Shah, Jennifer G. Brown, Doug Smith, Sergey Gorlatov, Valentina Ciccarone, James K. Tamura, Hua Li, Jill R. Rillema, Monica Licea, Christine Shoemaker, Leilei He, Farha Vasanwala, Jessica Hill, Arin Whiddon, Massimiliano Pascuccio, Shereen Saini, Francine Z. Chen, Anushka De Costa, Ann Easton, Peter Lung, Jonathan Li, Kurt Stahl, Jeffrey Nordstrom, Scott Koenig, Ezio Bonvini, Syd Johnson and Paul A. Moore

MGD019 (PD-1 x CTLA-4)

Keystone 2019 - MGD019, a PD-1 x CTLA-4 Bispecific DART® Molecule, Provides Simultaneous Blockade of PD-1 and CTLA-4 Checkpoint Pathways
Alexey Berezhnoy, Kurt Stahl, Kalpana Shah, Tim Gaynutdinov, Daorong Liu, Ross La Motte-Mohs R, Jessica Saul, Jonathan Li, Douglas Smith, Jill Rillema, Sergey Gorlatov, Valentina Ciccarone, Ralph Alderson, Hua Li, James Tamura, Jennifer Brown, Bradley Sumrow, Jon Wigginton, Ezio Bonvini, Syd Johnson, Paul A. Moore

CD32B

Therapeutic control of b-cell activation via recruitment of Fcgamma receptor IIB (CD32B) inhibitory function with a novel bispecific antibody scaffold
Veri M-C, Burke B, Huang L, Li H, Gorlatov S, Tuaillon N, Rainey JG, Ciccarone V, Zhang T, Shah K, Jin L, Ning L, Minor T, Moore PA, Koenig S, Johnson S, Bonvini E Arthritis Rheum 2010 Mar 30;62(7):1933-43.

Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization
Veri, M.C., Gorlatov, S., Li, H., Burke, S., Johnson, S., Stavenhagen, J., Stein, K. E., Bonvini, E., Koenig, S. Immunology. 2007 Jul;121(3) 392-404.

Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions
Boruchov, A.M., Heller, G., Veri, M.C., Bonvini, E., Ravetch, J.V., and Young, J.W. J. Clin. Invest. 2005 Oct; 115(10):2914-23.

Selective blockade of inhibitory Fc receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells
Dhodapkar, K.M., Kaufman, J.L., Ehlers, M., Banerjee, D.K., Bonvini, E., Koenig, S., Steinman, R.M., Ravetch, J.V., and Dhodapkar, J.V. Proc. Natl. Acad. Sci. USA 2005 Feb 22;102(8):2910-5.

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close